OP
NVCR icon

ORG Partners’s NovoCure NVCR Stock Holding History

ORG Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.45K Buy
+267
New +$3.43K ﹤0.01% 1327

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

ORG Partners's NVCR Position: Q4 2025 in Review

ORG Partners opened a new position in NovoCure (NVCR) in Q4 2025: 267 shares worth $3.45K. The stake represents ﹤0.01% of the portfolio and ranks #1327 among its holdings.

238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • ORG Partners held 267 shares of NovoCure worth $3.45K as of Q4 2025.
  • NovoCure was a new ORG Partners position in Q4 2025.
  • NovoCure made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1327 holding.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.